TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05892718: A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Sponsor: FBD Biologics Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT05892718 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05892718 Rescue Dossier →